HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline Clin Breast Cancer - 2 weeks
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials Eur J Cancer - 3 weeks
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials Eur J Cancer - 3 weeks
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	everolimus Sensitive: A1 - Approval
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CaT Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	docetaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	bevacizumab Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ixabepilone Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	toremifene Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant + anastrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant + letrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	abemaciclib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	exemestane Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline
ER positive + PGR positive ER positive + PGR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	EC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CMF Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	AC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TAC Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GT Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	epirubicin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	cyclophosphamide oral Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	lyso-thermosensitive liposomal doxorubicin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	estradiol Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	megestrol Sensitive: A2 - Guideline
HR negative + PD-L1 expression HR negative + PD-L1 expression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	pembrolizumab Sensitive: A2 - Guideline
HR negative + PD-L1 expression HR negative + PD-L1 expression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	atezolizumab Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline
PGR positive PGR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline
PGR positive PGR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	exemestane Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	POL 6326 Sensitive: B - Late Trials
PIK3CA mutation + ER positive PIK3CA mutation + ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PI3K inhibitor Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	DJ 927 Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SNDX-275 Resistant: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	capecitabine + DJ 927 Sensitive: B - Late Trials
ER positive + PGR negative + HER-2 negative ER positive + PGR negative + HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK6 inhibitor Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK4 inhibitor Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	chidamide Sensitive: B - Late Trials
PIK3CA E542K + HR positive PIK3CA E542K + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials
PIK3CA H1047X PIK3CA H1047X	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials
PIK3CA E545X PIK3CA E545X	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials
TP53 mutation TP53 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Resistant: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SHR6390 Sensitive: B - Late Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	Aromatase inhibitor + palbociclib Resistant: B - Late Trials
HIF1A overexpression HIF1A overexpression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: B - Late Trials
BACH1 overexpression BACH1 overexpression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	oral paclitaxel/encequidar Sensitive: B - Late Trials
BRCA1 mutation+ HER-2 negative BRCA1 mutation+ HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: B - Late Trials
BRCA2 mutation + HER-2 negative BRCA2 mutation + HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	neratinib Sensitive: C1 - Off-label
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	exemestane Sensitive: C1 - Off-label
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: C1 - Off-label
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BKM120 Sensitive: C2 – Inclusion Criteria
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: C2 – Inclusion Criteria
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-0077 Sensitive: C2 – Inclusion Criteria
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: C2 – Inclusion Criteria

HER2 Negative Breast Cancer

Associations(272)

Associations
(272)